Persistence of chromosomal aberrations in blood lymphocytes 11 years after cessation of CMF therapy in a breast cancer patient.
Chromosomal aberrations were examined in a breast cancer patient 11 years after cessation of cyclophosphamide methotraxate and 5-fluorouracil (CMF) therapy. This indicates that they may well be derived from a population of genetically damaged progenitor cells, from which abnormal and possibly malignant cell clones may have been generated, and a fraction of these randomly occurring chromosome rearrangements appear to be 'stable'.
Udayakumar
A M
AM
Department of Pathology, Kidwai Memorial Institute of Oncology, Bangalore, India.
Bhargava
M K
MK
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy / Q000235:genetics*; D002869:Chromosome Aberrations / Q000235:genetics*; D002945:Cisplatin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D007621:Karyotyping; D008214:Lymphocytes / Q000187:drug effects; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D013997:Time Factors
D002945:Cisplatin; D005472:Fluorouracil; D008727:Methotrexate